Revumenib, an oral targeted therapy for rare leukemias, is projected to be cost-neutral for health plans over 3 years, ...

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...

Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 ...

The researchers behind the new AI system explained IPF is a good candidate for this type of technology, since existing ...

Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple ...

In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss ...

Smartphone-based home screening significantly boosts chronic kidney disease (CKD) diagnosis and follow-up care, enhancing ...

Panelists discuss how maintenance therapy should be tailored based on risk profiles, with standard-risk patients receiving ...

Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard ...

Panelists discuss how robust clinical evidence from major studies like the EPIC and OPERA trials demonstrates that ...

Panelists emphasize that the approval of menin inhibitors has transformed the treatment landscape for KMT2A-rearranged acute ...

A panelist discusses how personalized ITP care requires open conversations about testing costs, insurance coverage, and ...